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Abstract
Purpose To assess tobacco, alcohol, cannabis and benzodiaz-
epine use in methadone maintenance treatment (MMT) as
potential sources of variability inmethadone pharmacokinetics.
Methods Trough plasma (R)- and (S)-methadone concen-
trations were measured on 77 Australian and 74 Swiss
MMT patients with no additional medications other than
benzodiazepines. Simple and multiple regression analyses
were performed for the primary metric, plasma methadone
concentration/dose.
Results Cannabis and methadone dose were significantly
associated with lower 24-h plasma (R)- and (S)-methadone
concentrations/dose. The models containing these variables
explained 14–16% and 17–25% of the variation in (R)- and
(S)-methadone concentration/dose, respectively. Analysis of
61 patients using only CYP3A4 metabolised benzodiaze-
pines showed this class to be associated with higher (R)-
concentration/dose, which is consistent with a potential
competitive inhibition of CYP3A4.
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Conclusion Cannabis use and higher methadone doses in
MMT could in part be a response to—or a cause of—more
rapid methadone clearance. The effects of cannabis and
benzodiazepines should be controlled for in future studies on
methadone pharmacokinetics in MMT.
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Introduction
Methadone is the most widely used opioid replacement
treatment for opiate dependency. It is usually given as a
racemic mixture of (R)- and (S)-methadone, with (R)-
methadone accounting for most of the opioid effects.
Wide interindividual variability has been shown in the
clinical pharmacokinetics of methadone [1]. A 17-fold
variation was reported in plasma (R)-methadone
concentration-to-dose ratios in patients taking no other
medications, with a 41-fold variation among those taking
other medications [2]. Interindividual variability in the
function of cytochrome P450 (CYP) enzymes CYP2B6
and CYP3A4 may account for much of this variation
and may be due to genetic polymorphisms and environ-
mental factors, including the use of medications and
non-prescribed substances [1, 3]. ABCB1 genetic poly-
morphisms, which encode for the permeability efflux
transporter P-glycoprotein (P-gp), may also contribute to
the interindindividual variability of methadone plasma and
central nervous system pharmacokinetics [3, 4].
Methadone also displays large interindividual pharma-
codynamic variability [1], with polymorphisms in the mu
and delta opioid receptors and dopamine D2 receptors as
possible candidates for this variability [5, 6].
While numerous studies have found high levels of
alcohol, benzodiazepine, tobacco and cannabis use in
subjects receiving methadone maintenance treatment
(MMT) [7–16], there have been very few studies of
pharmacokinetic interactions of these substances with
methadone. Based on a study of MMT patients, Hallinan
et al. [17] reported that benzodiazepine (mostly diazepam),
but not alcohol, use was associated with lower plasma (R)-
methadone concentration adjusted for dose and body
weight (p=0.001) in patients taking no other known
medications. This result suggests that the use of some
benzodiazepines may increase the clearance of methadone
or be a response to increased inherent methadone clearance
[17]. However this study did not examine cannabis or
tobacco use. Other studies have found no acute effects of
diazepam on methadone pharmacokinetics [18, 19],
although diazepam has significant acute pharmacodynamic
effects in methadone maintained patients [20, 21].
Diazepam could theoretically decrease the clearance of
methadone by inhibiting CYP3A4 [22].
We have used an epidemiological approach to examine
the hypothesis that tobacco, alcohol, cannabis and benzo-
diazepine use in MMT may be sources of methadone
pharmacokinetic variability. The aim of our study was to
assess the effect of concurrent use of tobacco, alcohol,
cannabis and benzodiazepines on the 24-h trough plasma
concentrations of methadone.
Materials and methods
The data used in this study was collected independently
from MMT centers in Australia and Switzerland.
Australian study group
Data from the Australian study group have been previously
reported elsewhere [23] and include MMT patients who had
24-h trough methadone concentration testing (their previous
methadone dose supervised, a blood sample collected just
before the next dose, with no dose change in the preceding
2 weeks) at the time of routine blood tests, which are done
twice yearly. The study results reported here are derived
from a subset of this group—those patients who were not
taking any known medications other than methadone and
benzodiazepines.
Current prescribed medications and substance use data
were recorded at the time of pre-test or post-test counseling.
Substance use data were recorded by the physician (RH) as the
Occasions of Drug Use Index (ODUI) [24] for the previous
month, based on patient self-report with supportive evidence
derived from the clinic protocol of regular medical con-
sultations and urine toxicology. These occur generally every
1 to 4 weeks, depending on progress in treatment according
to clinical indicators, including previous urine toxicology
results. A physician is available to see patients whenever the
clinic is open, such as when drug or alcohol use affects a
patient's presentation. Positive urine tests do not lead to
punitive actions, but they are indicators for more intensive
engagement including more frequent urine tests.
Initial toxicology screening is carried out with an
enzyme immunoassay (Microgenics CEDIA, Fremont,
CA) for opiates, benzodiazepines and metabolites, canna-
binoids, sympathomimetic amines, cocaine metabolites,
barbiturates, with follow-up thin layer chromatography
testing (Toxilab; Ansys Technologies, Lake Forest,
CA) as required, including that for codeine, morphine/
monoacetylmorphine, amphetamine/methamphetamine
and pseudoephedrine.
Collection of these data and their group-wise analysis
for purposes of clinical audit and potential publication
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was reviewed by the Ethics Committee at Central
Sydney Area Health Service (CSAHS Protocol Nr
X04-0030 "Audit Activities at the Byrne Surgery"). All
patients gave informed consent to urine and blood
testing.
Swiss study group
Data from the Swiss study group have been previously
reported elsewhere [3] and includes 276 patients in MMT at
five methadone-dispensing centers in Geneva, Lausanne,
Bern and Montreux (Switzerland). For the study reported
here, patients who were not taking any known medications
other than benzodiazepines were selected from among those
who were receiving once daily methadone dosing and who
also had a measured trough methadone concentration.
Classification of current substance use status was by subject
self-report of the frequency of use during the previous
3-month period (never; up to 2×/week; 3×/week or more) in
a confidential questionnaire. The only exception to this was
the test for heroin and cocaine use, where classification was
confirmed by the presence or absence of positive urines for
opiates or cocaine metabolites over a period of 3 months
prior to inclusion, with urine tests randomly performed at
least once a week (this reflects the protocols of the original
studies). Subjects were assured that no negative conse-
quences would result from self report. Information on
prescribed medications was available from the medical files
of the patients. The study was approved by the local ethics
committees of the participating centers, and written
informed consent was obtained from all patients.
Data
Main outcome measures were trough plasma (R)- and (S)-
methadone concentration adjusted for methadone dose by
dividing the plasma (R)- and (S)-methadone concentration
for each subject by their daily dose. This composite
measure is widely used [1, 2] and has the benefit of being
a better reflection of the bioavailability and clearance of
methadone than unadjusted methadone concentrations,
whereas adjustment for body weight is now accepted to
be inappropriate [23, 25].
Other clinical data collected were: age, gender, body
weight, body mass index (BMI), duration of current
methadone treatment episode. Substance use data were
treated as categorical variables, as follows:
& alcohol intake—exceeding or not exceeding low-risk
drinking limits, i.e. 40 g/day or 280 g/week for men and
20 g/day or 140 g/week for women [26];
& smoking—current smokers and non-smokers of
tobacco;
& cannabis use—current users and non-users (any use at
all in reference period);
& heroin use—current users and non-users (any use at all
in reference period);
& benzodiazepine use—those currently using benzodia-
zepines, whether prescribed or non-prescribed (any
use at all in reference period; note patients taking
zolpidem and zopiclone were excluded).
The periods of reference for alcohol, cannabis, heroin
and benzodiazepine use were "last 30 days" for the
Australian groups and "last 3 months" for the Swiss groups.
The above limits for alcohol use were chosen as a
convenient measure for dichotomizing alcohol consumption
and have no particular significance for methadone metab-
olism or efficacy in MMT.
Analysis of (R)-methadone and (S)-methadone
by high-performance liquid chromatography
For the Australian Study Group, plasma was separated from
the blood samples within 4 h, and the specimens were
transported to the laboratory where they were frozen and
stored at −20°C until testing. Analysis of (R)-methadone
and (S)-methadone was performed by high-performance
liquid chromatography (HPLC) adapted from [28]. Cali-
bration curves for (R) and (S)-methadone were linear over
the concentration range 20–1000 ng/mL with a coefficient
of variance (CV) ≤6.3%. The limit of quantitation was
20 ng/mL with a CV > 10.3% and deviation from the
nominal value of less than 2.5%.
For the Swiss study group, plasma was separated from
the ethylenediaminetetraacetic acid-treated blood samples
and the specimens stored at −20°C until testing. Analysis of
(R)-methadone and (S)-methadone was performed by liquid
chromatography coupled with mass spectroscopy as previ-
ously described [27, 29, 30]. The method was fully
validated over a concentration range of 5–800 ng/mL for
each methadone enantiomer with satisfactory relative bias
(−1.0 to 1.0%), repeatability (0.9–4.9%) and intermediate
precision (1.4–12.0%).
Data analysis
Simple and multiple regression analyses, including back-
ward stepwise regression, were performed on both data sets
separately for the effects of gender, age, months of
treatment, daily methadone dose and use versus non-use
of tobacco, alcohol, heroin, cannabis and benzodiazepines
on outcome measures. Duration of treatment and daily dose
were included as variables, owing to reports that methadone
might induce its own metabolism at the beginning of
treatment [25, 31, 32]. Multiple linear regression models
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were evaluated for normality of residuals and homogeneity
of variance. Statistical analyses were undertaken with the
statistical package STATA, ver. 8.2 and 9.2 (2004; Stata
Corporation, College Station, TX). Statistical significance
was taken as P≤0.05. Summary measures are presented as
the mean ± standard deviation (SD) for normally distributed
data, and as the median with 25th and 75th percentiles for
non-normally distributed data.
Results
Among the Australian study group, 77 of 158 patients
receiving MMT between June and December 2003 met
the inclusion criteria and were using no medications
other than benzodiazepines and methadone, with blood
samples taken at a mean 24.3 h (SD 1.2 h) after a
witnessed dose. From the Swiss Study group, results
were available for a total of 74 patients who were using
no medications other than benzodiazepines and metha-
done: for all but eight of these patients there was no dose
change in the 2 weeks preceding blood testing, and the
minimum duration since the last dose change for these
eight patients was 4 days. Blood samples were taken at a
mean 23.3 h (SD 3.6 h) after a witnessed dose.
Table 1 shows summary statistics for the two study
groups. Recent cannabis, benzodiazepine and tobacco use
were common in both study groups (for Australian and
Swiss groups, respectively: 46 vs. 57%; 36 vs. 46%; 83 vs.
96%), while alcohol use exceeding low-risk limits was
more common in the Swiss group (38 vs. 16%) and recent
heroin was use less common (15 vs. 48%). Prescribed
diazepam was the benzodiazepine primarily reported by 14
of 28 benzodiazepine users in the Australian study group,
with smaller numbers reporting use of prescribed alprazo-
lam (one patient), oxazepam (two) and 11 patients reporting
the use of whichever benzodiazepine was opportunistically
available. This was most commonly diazepam, according to
general patient report and the doctors' knowledge of
benzodiazepine availability in the area, and less commonly
oxazepam, alprazolam or clonazepam. A greater range of
benzodiazepines used was reported from the Swiss study
groups: oxazepam (11 patients), clonazepam (six), cloraze-
pam (four), lorazepam (four), bromazepam (five), alprazo-
lam (three), midazolam (four), diazepam (two), flurazepam
(two), flunitrazepam (one) and triazolam (one).
Table 1 Demographic and plasma methadone concentrations summary statistics—dependent and independent variables for the Australian and
Swiss study groups
Variable Australian Study Group (n=77) Swiss Study Group (n=74)
Duration of MMT, monthsa 31 (11–102) 45 (15–89)
Age, yearsb 36.6 (7.6) 36.8 (8.2)
Weight, kgb 72.9 (14.5) 75.2 (15.7)
Body mass index, kg/m2b 24.3 (4.2) 24.2 (4.9)
Methadone dose, mg/daya 95 (50–140) 82.5 (45, 150)
Time since previous supervised dose, hb 24.3 (1.2) 23.3 (3.6)
Plasma (R)-methadone concentration, ng/mLa 160 (85–229) 166 (91–281)
Plasma (R)-methadone/dose, ng × day/mL × mgc 1.8 (0.7; 0.65–3.81) 2.2 (1.7; 0.6–12.8)
Plasma (S)-methadone concentration, ng/mLa 138 (80–190) 157 (89–254)
Plasma (S)-methadone/dose (ng × day/mL × mgc 1.7 (0.8; 0.4–4.1) 2.1 (2.0; 0.2–15.0)
Plasma (R,S)-methadone concentration, ng/mLa 304 (150–435) 336 (177–546)
Plasma (R,S)-methadone/dose, ng x day/mL × mgc 3.4 (1.4; 1.1–7.9) 4.3 (3.7; 1.0–27.7)
Plasma (R)/(S)-methadone ratioc 1.1 (0.3; 0.6–2.0) 1.2 (0.4; 0.7–3.4)
Gender male (%) 60/77 (77.9%) 59/74 (79.7%)
Current cannabis use (%) 35/77 (45.5%) 42/74 (56.8%)
Current benzodiazepine use (%) 28/77 (36.4%) 34/74 (46.0%)
Exceeding low risk alcohol limits (%) 12/77 (15.6%) 28/74 (37.8%)
Tobacco smokers (%) 64/77 (83.1%) 71/74 (96.0%)
Current heroin use (%) 37/77 (48%) 11/74 (14.9%)
MMT, Methadone maintenance treatment; SD, standard deviation;
a Values are given as the median with 25th and 75th percentiles
b Values are given as the means ± SD
cValues are given as the mean with the SD and range given in parenthesis
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As shown in Figs. 1 and 2, there was substantial overlap
between benzodiazepine and cannabis use in the Australian
group, and among benzodiazepine, alcohol and cannabis
use in the Swiss group.
Lower 24-h trough plasma (R)-methadone concentration/
dose ratios were significantly associated with the following
variables (Supplementary table): higher methadone dose
(Australian group R2 = 0.072, P = 0.019; Swiss group R2 =
0.072, P = 0.021); cannabis use (Australian group R2 =
0.088, P = 0.009; Swiss group R2 = 0.087, P = 0.011);
benzodiazepine use (Australian group only R2 = 0.060,
P = 0.032); alcohol use (Swiss group only R2 = 0.059,
P = 0.037); heroin use (Swiss group only R2 = 0.069,
P = 0.024).
Lower 24-h trough plasma (S)-methadone concentration/
dose ratios were significantly associated with the following
(Supplementary table): higher methadone dose (Australian
group R2 = 0.176, P < 0.001; Swiss group R2 = 0.103, P =
0.005); cannabis use (Australian group R2 = 0.076, P =
0.015; Swiss group R2 = 0.083, P = 0.013; heroin use
(Australian group R2 = 0.0381, P = 0.049; Swiss group
R2 = 0.063, P = 0.032); benzodiazepine use (Australian
group only R2 = 0.099, P = 0.005); alcohol use (Swiss
group only R2 = 0.055, P = 0.044). No significant
associations were found between (R)- or (S)-methadone
concentration/dose ratios and duration of MMT, age,
weight, BMI, gender or tobacco smoking in both groups
(data not shown).
After backward stepwise regression (Table 2), cannabis
and methadone dose remained significantly associated with
lower 24-hour trough plasma (R)-methadone/dose and (S)-
methadone/dose for both study groups. The models
containing these variables explained 16 and 25% of the
variation in plasma (R)- and (S)-methadone/dose ratios,
respectively, for the Australian study group and 14% and
17% for the Swiss study group.
An additional analysis was performed for the Swiss
group after excluding those receiving oxazepam and
lorazepam, which are mainly glucuronidated with no
significant contribution of CYP3A4 in their metabolism.
As shown in Table 2, cytochrome P450 metabolized
benzodiazepines remained in the multivariate model for
this group (n=61), associated with higher trough plasma
(R)-methadone/dose.
Discussion
After stepwise regression, cannabis use and higher daily
methadone dose were found in both study groups to be
significantly and negatively associated with 24-h trough
(R)-methadone/dose and (S)- methadone/dose; the latter
were not associated with gender, alcohol, tobacco smoking
or duration of MMT treatment. Multiple regression also
revealed that body weight and BMI were unrelated to
24-h methadone concentration/dose, which is consistent
with a previous report that methadone clearance is unrelated
to body weight [25].
An association of higher methadone dose with lower
methadone plasma concentration/dose ratio has been
previously reported [2, 25] and may be explained by the
induction of drug metabolism at higher methadone doses
and/or saturation of plasma binding, which would lower the
total plasma concentration/dose ratio without affecting
unbound concentrations.
An association of cannabis use with lower plasma
(R)-methadone/dose and (S)-methadone/dose has not been
previously reported. One possible pharmacokinetic expla-
nation could be induction of the isoenzyme CYP1A2 by
smoke, leading to the increased metabolism of methadone;
however, no association of tobacco smoking with trough
methadone concentrations was found in our study nor in
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previous ones [3]. As the ABCB1 3435TT genotype is
associated with lower P-gp activity as well as slightly
lower trough (R,S)-methadone plasma concentrations [3],
another possible explanation involves P-gp inhibition by
cannabinoids [33].
Alternatively, as the plasma methadone concentration–
response relationship for withdrawal and mood symptoms
is very steep [34, 35], cannabis use may be a compensatory
response to opioid withdrawal symptoms in some individ-
uals who have more rapid methadone clearance.
Contrary to data reported earlier by the Australian Study
Group [17], subsequent multivariate analysis revealed no
evidence of a relationship between benzodiazepine use and
lower 24-h trough plasma methadone/dose. Although the
Australian Study Group found that the most common
benzodiazepine used was diazepam (according to patient
report), patients can obtain benzodiazepines by visiting
multiple doctors; in addition, benzodiazepines are readily
available on the black market. Consequently, patients may
use a range of benzodiazepines, depending on what is
available. By contrast, the Swiss group generally used
benzodiazepines prescribed by their methadone prescribing
doctor, and analysis of the subgroup using CYP3A4
metabolized benzodiazepines showed this class to be
associated with higher trough plasma (R)-methadone/dose,
which is consistent with a potential competitive inhibition
of CYP3A4.
The results for (S)-methadone/dose generally paralleled
those for (R)-methadone/dose; however, the association of
higher methadone dose with lower trough methadone
concentration/dose was substantially stronger for (S)--
methadone. Differences in the clearance of (R)- and (S)-
methadone may be of clinical importance as (S)-methadone
has been incriminated in dysphoric effects at higher
methadone doses [36] and shown to be a more potent
hERG current inhibitor than (R)-methadone, with a higher
risk for methadone-induced QT interval prolongation [37].
The limitations of this study should be mentioned. The
validity of self-report measures of substance use may be
questioned, with the potential systematic bias that MMT
subjects may under-report their use of other substances.
However, self-report of substances using populations has a
high validity [38, 39], especially where honest self-
reporting is encouraged without being linked to negative
consequences [40, 41], as was true for both study groups
described here. Self-report can reveal substance use not
detected by urine analysis, which only detects recent use
[39, 42, 43]. In a clinical setting, optimum results may be
achieved by combining urine tests and self-reported drug
use [44, 45], as occurs at the Australian Study Center and
also partially at the Swiss Study Center.
The categorization of subjects as current users and non-
users of substances is rudimentary as it gives no indication
of the amount or frequency of use. Cannabis use in
Table 2 Stepwise regression for (R)-methadone/dose and (S)-methadone/dose
Variable (R)-Methadone/dose (ng day/mL mg) (S)-Methadone/dose (ng day/mL mg)
Coefficient (SE) P value 95% CI Coefficient (SE) P value 95% CI
Australian Study Group (n=77)
Methadone dose (mg/day) −0.003 (0.001) 0.015 −0.005 to −0.001 −0.005 (0.001) <0.001 −0.008 to −0.003
Cannabis (current users vs. non-users) −0.393 (0.142) 0.007 -0.678 to −0.109 −0.431 (0.160) 0.009 −0.750 to −0.112
Constant 2.239 (0.149) 0.000 1.942–2.536 2.411 (0.167) 0.000 2.077– 2.744
(R2=0.1582; P=0.002) (R2=0.2496; P<0.0001)
Swiss Study Group (n=74)
Methadone dose (mg/day) −0.005 (0.002) 0.034 −0.009 to −0.0004 −0.007 (0.003) 0.009 −0.012 to −0.002
Cannabis (current users vs non-users) −0.931 (0.382) 0.017 −1.693 to −0.169 −1.052 (0.447) 0.021 −1.942 to−0.162
Constant 3.259 (0.367) 0.000 2.527– 3.992 3.505 (0.429) 0.000 2.649–4.360
(R2=0.1433; P=0.004) (R2=0.1680; P=0.002)
Swiss Study Group (n=61)a
Methadone dose (mg/day) −0.007 (0.003) 0.012 −0.013 to −0.002 −0.008 (0.003) 0.013 −0.014 to −0.002
Cannabis (current users vs. non-users) −1.146 (0.437) 0.011 −2.020 to −0.271 −1.213 (0.524) 0.024 −2.263 to −0.164
Benzodiazepine (1) 0.995 (0.484) 0.045 0.025–1.964 Not applicableb
Constant 3.352 (0.428) 0.000 2.495–4.209 3.750 (0513) 0.000 2.723–4.776
(R2=0.2070; P = 0.004) (R2=0.1771; P=0.004)
CI, Confidence interval; SE, standard error
a Excluding users of oxazepam and lorazepam
bNot significant in the multivariate analysis and therefore not included in the model
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particular is difficult to quantify, owing to the variety of
methods of smoking and of the different potencies of the
cannabis smoked. Allowing that MMT subjects may under-
report their use of other substances and that information is
lost in categorical classification, these factors would bias
results towards the null, implying the significant associa-
tions of cannabis use identified in this study may be
stronger in reality.
An inherent limitation of the epidemiological methodology
of our study is that it is not capable of determining the causal
direction of the associations found. It should also be noted that
neither study group was selected to be representative of their
respective MMT populations; differences in the univariate
analyses for these groups may reflect different rates of alcohol
and heroin use, or the differing methods and periods (1 vs. 3
months) of substance use assessment. However it is likely that,
for most MMT patients, the use of benzodiazepines, cannabis
and tobacco is relatively constant over such time frames.
The major strength of the study lies in its replication of
findings in two independent and transnational study
populations. These findings are all the more robust given
the differences in the methods used by the Australian and
Swiss groups to derive substance use data.
If the lower trough methadone concentrations/dose
reported in this study actually do reflect methadone
clearance, cannabis use and higher methadone doses in
MMT may be either a response to—or cause of—more
rapid methadone clearance. If the former, one would expect
benzodiazepines, depending on their availability, to be used
by patients in a similar way. However, we found no
indication of this in our study. If the latter, the coefficients
of variation (R2) on univariate analysis suggest that
cannabis use may explain about 9% and methadone dose
about 7% of the interindividual variation of the plasma (R)-
methadone/dose ratio. Although in the cross-sectional
analysis the scale of these associations is modest compared
to the overall interindividual variation, their effects may be
more substantial within individuals.
Conclusion
Cannabis use is common in MMT and may be considered
by clinicians to be of minor importance. This study
suggests the need for further experimental and clinical
studies of the effects of cannabis on methadone pharmaco-
kinetics. Future clinical studies of possible effects of
benzodiazepines on methadone metabolism will require
control for the effects of other substances, especially
cannabis, and of the type of benzodiazepine used.
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